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ABSTRACT
Introduction: The broth microdilution method
(BMD) for testing telavancin minimum
inhibitory concentrations (MICs) was revised
(rBMD) in 2014 to improve the accuracy,
precision, and reproducibility of the testing
method. The aim of this study was to
determine the effect of the revised method on
telavancin MIC values for Staphylococcus aureus
(S. aureus) clinical isolates obtained from
hospital-acquired pneumonia (HAP) patients.
Methods: Isolates from patients who
participated in the phase 3 Assessment of
Telavancin for Treatment of HAP Studies were
retested using the rBMD method.
Results: Retesting of 647 isolates produced a
range of telavancin MIC values from 0.015 lg/
mL to 0.12 lg/mL with MIC50/90 values of 0.06/
0.06 lg/mL for the total pool of samples. For
methicillin-resistant S. aureus (MRSA), MIC50/90
values were 0.06/0.12 lg/mL. These values are
up to 4-fold lower than MIC50/90 values
obtained using the original method. These
results were used in part to justify lowering
the telavancin breakpoints. All tested isolates
remained susceptible to telavancin at the
revised susceptibility breakpoint of B0.12 lg/
mL. Overall, the clinical cure rate for
microbiologically evaluable telavancin-treated
patients was 78% for S. aureus, 76% for patients
with MRSA, and 79% for patients with isolates
with reduced susceptibility to vancomycin (MIC
C1 lg/mL).
Conclusion: Results from the rBMD method
support the in vitro potency of telavancin
against S. aureus.
Trial registration: ATTAIN (NCT00107952 and
NCT00124020).
Funding: Theravance Biopharma Antibiotics,
Inc.
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Staphylococcus aureus (S. aureus) infections are a
major cause of pneumonia and are especially
implicated in hospital-acquired pneumonia
(HAP), ventilator-associated pneumonia (VAP),
and healthcare-associated pneumonia [1]. The
recent Infectious Diseases Society of America
guidelines recommend treating HAP/VAP
patients with either vancomycin or linezolid
[2]. Higher vancomycin minimum inhibitory
concentrations (MICs) have been associated
with more frequent treatment failure and
higher mortality rates [3–6]. Telavancin
(Theravance Biopharma Antibiotics, Inc.,
George Town, Grand Cayman, Cayman
Islands) is a parenteral bactericidal
lipoglycopeptide antibiotic that has a dual
mechanism of action [7–10]. Telavancin is
approved in the US, Canada, Russia, and
Europe for treatment of HAP, including VAP
that is caused by susceptible isolates of S. aureus
(methicillin-resistant S. aureus [MRSA] only in
Europe). In the US, Russia, and Europe, the
indication is limited to infections in which
alternative medicines are unsuitable [8, 11, 12].
In the Assessment of Telavancin for Treatment
of Hospital-Acquired Pneumonia [ATTAIN
(ClinicalTrials.gov identifiers NCT00107952
and NCT00124020)] studies, a total of 1503
patients with HAP were treated with telavancin
or vancomycin for up to 21 days. Telavancin
demonstrated noninferiority to vancomycin,
achieving similar cure rates [13].
Drug loss due to binding to plastics in the
MIC assay has been found with other
lipoglycopeptides and is resolved with the
addition of polysorbate 80 (P-80) [14, 15]. To
improve the accuracy and precision of
telavancin susceptibility testing, a revised
broth microdilution method (rBMD) MIC
testing method for telavancin was approved
by the US Food and Drug Administration
(FDA) and published by Clinical and
Laboratory Standards Institute (CLSI) in
2014 to include dimethyl sulfoxide (DMSO)
in the diluent to improve solubility and P-80
in the broth microdilution assay
cation-adjusted Mueller–Hinton broth
(CAMHB) to reduce drug loss due to binding
to plastic [8, 16, 17]. This revised method has
produced up to 8-fold lower telavancin MIC
results compared with the previous method
[17] and has been used to establish new
values for telavancin activity against a
variety of clinical isolates [18, 19]. The FDA
and CLSI previously have approved B0.12 lg/
mL as the telavancin MIC susceptibility
breakpoint for S. aureus [both
methicillin-susceptible S. aureus (MSSA) and
MRSA] isolates; intermediate or resistant
breakpoints for telavancin have not been
established as of 2016, due to the rarity of
telavancin-resistant S. aureus isolates [8, 20].
The objective of this study was to determine
the effect of the revised method on
telavancin MIC values for S. aureus clinical
isolates obtained from the ATTAIN HAP/VAP
patients and evaluate the clinical outcome by
the revised telavancin MICs. These results
were part of the data package presented to
breakpoint setting committees, including
FDA, CLSI, and the European Committee on
Antimicrobial Susceptibility Testing for the
evaluation of the revised telavancin
breakpoints.
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METHODS
Patient Population and Study Procedures
The protocol for the ATTAIN studies has been
presented elsewhere [13]. Briefly, these were
identical, randomized, double-blind,
comparator-controlled phase 3 trials
(ClinicalTrials.gov identifiers NCT00107952
and NCT00124020) in which inpatients who
developed pneumonia caused by Gram-positive
infections were randomized to receive
telavancin (10 mg/kg every 24 h) or
vancomycin (1 g every 12 h) for 7 to 21 days
[13]. The primary endpoint of the study was the
investigator-assessed clinical response at a
follow-up/test-of-cure visit between 7 and
14 days after the last dose of study medication.
Respiratory and blood culture specimens were
collected at baseline, and isolates underwent
susceptibility testing and confirmation at a
central laboratory (Covance Laboratories,
Indianapolis, IN, USA; Duke Clinical Research
Institute, Durham, NC, USA).
Clinical cure rates by MIC reported in the
ATTAIN trials were reassessed using the MICs
obtained using the rBMD method. In the
ATTAIN studies, the clinically evaluable study
population consisted of patients who met study
inclusion criteria and adhered to study protocol
such that their clinical outcome could be
considered to accurately reflect the effects of
study medication. The microbiologically
evaluable population in the ATTAIN studies
included all clinically evaluable patients who
had a Gram-positive (S. aureus in this analysis)
respiratory pathogen at baseline. Presumed
microbiological eradication was defined as
failing to identify the baseline pathogen in the
last postbaseline culture or if the patient was
clinically cured and there were no follow-up
cultures available.
rBMD
The analysis of the effects of telavancin on
clinical isolates from the ATTAIN studies was
performed using the rBMD method at JMI
Laboratories (North Liberty, IA, USA).
Telavancin stock solutions of 1600 lg/mL were
prepared by dissolving dry powder in DMSO in
a glass vial; stock solutions were further diluted
in DMSO to achieve intermediate
concentrations ranging from 0.004 to 8 lg/mL,
per CLSI recommendations [16]. The
telavancin/DMSO solutions were further
diluted 1009 in CAMHB containing 0.002%
(volume/volume) P-80 (Tween 80; Croda
International, Snaith, UK) to minimize
adhesion to plastic surfaces. Following
dilution, 100-lL aliquots of telavancin
solutions ranging in concentration from 0.004
to 8 lg/mL were dispensed into 96-well plates.
Comparator agents tested against the same S.
aureus isolates included linezolid (MIC range
0.25–4 lg/mL), ampicillin (MIC range
0.25–32 lg/mL), and vancomycin (MIC range
0.25–16 lg/mL).
Clinical Isolates
Isolates were sent from the ATTAIN study
central laboratories (Covance Laboratories) to
JMI Laboratories for retesting using the rBMD
method. The isolates were stored at -80 C at
Covance, then were shipped to JMI laboratories
on dry ice, where they were stored at -80 C.
Minimum inhibitory concentration values were
assessed for S. aureus isolates from the ATTAIN
studies. Sample quality was assured via
concurrent testing of CLSI-recommended
quality control (QC) reference strains (S. aureus
American Type Culture Collection [ATCC]
29213, Enterococcus faecalis ATCC 29212, and
S. pneumoniae ATCC 49619, Manassas, VA,
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USA). All QC MIC results for control strains
were within acceptable ranges defined by CLSI
[16].
Statistical Analyses
All the analyses were descriptive and performed
using SAS 9.4 software (Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
A total of 647 S. aureus isolates from patients
with HAP in the ATTAIN studies were analyzed
for telavancin MICs using the rBMD method
(644 samples were tested using the original
method). Three isolates that did not have an
initial central laboratory MIC result and were
not included in the original susceptibility
analysis were included in this set of retested
isolates. Overall, 240 isolates were MSSA
isolates, and 407 were MRSA isolates.
The MIC values obtained using the rBMD
method for telavancin and control agents tested
against ATTAIN S. aureus isolates were within
the CLSI-approved and accepted QC ranges
determined using S. aureus ATCC 29213
(telavancin 0.03–0.12 lg/mL, ampicillin
0.5–2.0 lg/mL, linezolid 1.0–4.0 lg/mL,
vancomycin 0.5–2.0 lg/mL) [16].
Telavancin MICs for all S. aureus isolates
ranged from 0.015 to 0.12 lg/mL, with a range
of 0.015 to 0.12 lg/mL for MSSA isolates and
0.015 to 0.12 lg/mL for MRSA isolates (Table 1).
For the overall set of S. aureus isolates and for
MSSA isolates, telavancin MIC50/90 values were
0.06/0.06 lg/mL; for MRSA, the telavancin
MIC50/90 values were 0.06/0.12 lg/mL. These
results represent a substantial downward shift in
telavancin MIC values for S. aureus compared
with the MICs obtained using the original
method (Fig. 1), which produced higher values
of MICs for telavancin (MIC50/90 of 0.25/
0.50 lg/mL for the total pool of S. aureus
isolates).
Among the 528 isolates with reduced
susceptibility to vancomycin (MIC C1 lg/mL),
telavancin MIC50/90 values obtained using the
rBMD method were 0.06/0.12 lg/mL. Among
these samples, 166 were MSSA and 362 were
MRSA, with MIC50/90 values of 0.06/0.06 lg/mL
for MSSA and 0.06/0.12 lg/mL for MRSA,
respectively (Table 1). These values were lower
than the telavancin MIC50/90 values for isolates
with reduced vancomycin susceptibility
generated by the original method, which were
0.25/0.5 lg/mL and 0.5/0.5 lg/mL for MSSA and
MRSA, respectively. The isolates with reduced
susceptibility to vancomycin remained
susceptible to telavancin (rBMD MIC50/90)
when using the revised FDA-approved
breakpoint of\0.12 lg/mL [8].
A total of 183 isolates exhibited a ±1 dilution
change in the vancomycin MIC C1 lg/mL upon
retesting. Of those, 1 increased from 0.25 to
0.5 lg/mL, 110 increased from 0.5 to C1 lg/mL,
11 increased from 1 to 2 lg/mL, 50 decreased
from 1 to 0.5 lg/mL, and 11 decreased from 2 to
1 lg/mL. A total of 2 isolates exhibited a
2-dilution change in the vancomycin MIC
upon retesting with 1 increasing from 0.5 to
2.0 lg/mL and 1 decreasing from 2.0 to 0.5 lg/
mL. These changes can be attributed to random
testing differences between two laboratories
(Table 1).
The clinical cure rate by revised MIC was
assessed in the microbiologically evaluable
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population of telavancin-treated patients (195
patients). The overall telavancin clinical cure
rate for S. aureus was 78% (153/195 patients),
with clinical cure rates of 83% (62/75 patients)
and 76% (91/120 patients) for MSSA- and
MRSA-infected patients, respectively (Table 2).
The clinical cure rate did not decrease with
increasing telavancin MIC values for S. aureus
obtained using the rBMD method, which
ranged from 0.03 to 0.12 lg/mL, as clinical
cure rates remained C81% and C70% for MSSA-
and MRSA-infected patients, respectively, for all
MIC values (Table 2). Among the 166
microbiologically evaluable telavancin-treated
patients with S. aureus isolates that
demonstrated reduced susceptibility to
vancomycin (MIC C1 lg/mL), the clinical cure
rate was 79% (131/166 patients) for telavancin.
The microbiological eradication rates for the
overall S. aureus, individual MSSA and MRSA
isolates, and isolates with reduced vancomycin
susceptibility (MICs C1 lg/mL) were
comparable (Table 2) [13].
DISCUSSION
Lipoglycopeptide drug loss due to its binding to
plastics is known to affect the MIC
determination. The addition of P-80 to the
MIC assay has resolved this issue and the
FDA-approved rBMD method includes DMSO
and P-80 to improve drug solubility and reduce
drug loss, respectively [8, 14–17]. Telavancin is a
lipoglycopeptide active against a wide range of
susceptible Gram-positive pathogens, including
S. aureus [13]. The objective of this study was to
Table 1 Distribution of telavancin MIC values obtained using rBMD on HAP isolates from ATTAIN trials
Organism Method MIC (lg/mL)




S. aureus (all) Revised 647 3 167 413 64a – – – 0.015–0.12 0.06/0.06
Original 644 – – 2 13 346 258 25 0.06–1 0.25/0.50
MSSA Revised 240 1 94 144 1 – – – 0.015–0.12 0.06/0.06
Original 239 – – – 10 178 50 1 0.12–1 0.25/0.5
MRSA Revised 407 2 73 269 63 – – 0.015–0.12 0.06/0.12
Original 405 – – 2 3 168 208 24 0.06–1 0.5/0.5
S. aureus vancomycin MIC
C1 lg/mL
Revised 528 – 94 370 61 3a – – 0.03–0.25 0.06/0.12
Original 466 – – – 7 229 209 21 0.12–1 0.25/0.5
MSSA vancomycin MIC
C1 lg/mL
Revised 166 – 48 117 1 – – – 0.03–0.12 0.06/0.06
Original 137 – – – 5 103 29 – 0.12–0.5 0.25/0.5
MRSA vancomycin MIC
C1 lg/mL
Revised 362 – 46 253 60 3 – – 0.03–0.25 0.06/0.12
Original 329 – – – 2 126 180 21 0.12–1 0.5/0.5
Data presented as number of isolates except where indicated
ATTAIN Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; HAP hospital-acquired pneumonia;
MIC minimum inhibitory concentration; MRSA methicillin-resistant S. aureus; MSSA methicillin-susceptible S. aureus;
rBMD revised broth microdilution; S. aureus Staphylococcus aureus
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re-evaluate the ATTAIN clinical isolates with the
rBMD method that has previously
demonstrated lower telavancin MIC values
[8, 16, 17].
Telavancin MIC values for MSSA and MRSA
obtained using the rBMD method were lower
than those that have been published elsewhere
using the original method [21, 22], indicating
that telavancin is more active in vitro against S.
aureus isolates than previously considered. In
this study, the rBMD method produced an
overall 4-fold decrease in the telavancin
MIC50/90 for S. aureus compared with the
original method. All isolates were susceptible
to telavancin, consistent with other studies
reporting telavancin susceptibility of S. aureus
using the rBMD method [18, 19]. Telavancin
also retained its in vitro potency against isolates
with reduced susceptibility to vancomycin (MIC
C1 lg/mL). Furthermore, the reassessment of
ATTAIN study clinical isolates using the rBMD
method demonstrated robust clinical cure and
microbiological eradication even at the highest
telavancin MIC (0.12 lg/mL) observed in the
study.
This study is limited by its retrospective
nature. The patients were not prospectively
stratified by MIC and the reduced sample size
prevented extensive statistical analyses of the
clinical cure rates. However, the
Clopper–Pearson (Exact) confidence interval
method [22] was applied to demonstrate that
the clinical cure rates were comparable across all





























































































































































Fig. 1 Distribution of telavancin MICs obtained using the
rBMD or original BMD method in a all S. aureus isolates,
b MSSA isolates, c MRSA isolates, and d S. aureus isolates
with vancomycin MICs C1 lg/mL. MIC minimum
inhibitory concentration; MRSA methicillin-resistant S.
aureus; MSSA methicillin-susceptible S. aureus; rBMD
revised broth microdilution; S. aureus Staphylococcus
aureus; VAN vancomycin
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CONCLUSION
Reassessment of the ATTAIN isolates using the
rBMD method demonstrated increased in vitro
potency of telavancin against S. aureus. These
data support lowering the telavancin
susceptibility breakpoint to 0.12 lg/mL for S.
aureus. Moreover, these results suggest that
published studies using the previous BMD
underestimated the in vitro potency of
telavancin [23, 24].
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